MedPath

Error parsing response

Error occurred while parsing the model response.

Error occurred while parsing the model response.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Greenwich LifeSciences Expands Phase III Breast Cancer Trial Globally, Adds New Sites and Expertise

Greenwich LifeSciences broadens its Phase III FLAMINGO-01 trial for GLSI-100, an immunotherapy aimed at preventing breast cancer recurrence, by adding new clinical sites in the U.S. and Europe.
The trial expands into France through a partnership with Unicancer, activating 19 sites, and collaborates with GBG in Germany, adding approximately 38 sites to the study.

Henlius to Present Latest Clinical Data of HLX10 and HLX22 at 2025 ASCO GI

Shanghai Henlius Biotech, Inc. will showcase the latest clinical data of its anti-PD-1 monoclonal antibody HANSIZHUANG (serplulimab) and innovative anti-HER2 monoclonal antibody HLX22 at the 2025 ASCO Gastrointestinal Cancers Symposium. The presentations will cover updated efficacy and safety profiles of these treatments in various gastrointestinal and lung cancer indications.

Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025

Immuneering Corporation announced it will hold a virtual Investor Event in early January 2025 to discuss data from its ongoing Phase 2a trial of IMM-1-104, including additional data from IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer, initial data from IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer, and initial data from IMM-1-104 monotherapy in second-line pancreatic cancer.

Greenwich LifeSciences Expands Breast Cancer Immunotherapy Trial to Italy

Greenwich LifeSciences partners with Gruppo Italiano Mammella (GIM) to expand its Phase III FLAMINGO-01 trial in Italy.
Nine top Italian institutions will participate in evaluating GLSI-100, an immunotherapy aimed at preventing breast cancer recurrence.

GENFIT to Initiate New ACLF Clinical Trials and Awaits Key Data Readouts in 2025

GENFIT plans to launch two new clinical trials in Q1 2025 focusing on Acute-on-Chronic Liver Failure (ACLF) with VS-01 and a new formulation of NTZ.
The trials will include patients with acute decompensation at high risk of progressing to ACLF, aiming to streamline trial execution and patient recruitment.

GENFIT Highlights Progress in PBC and ACLF Programs at The Liver Meeting 2024

GENFIT's partner Ipsen is making strides with Iqirvo® (elafibranor) for PBC, with encouraging U.S. launch feedback and European reimbursement approvals.
GENFIT is advancing its ACLF franchise, presenting preclinical data at The Liver Meeting and planning multiple clinical studies in 2025.

Rhenium-186 Obisbemeda Shows Promise in Recurrent Glioblastoma Trial

Plus Therapeutics' ReSPECT-GBM Phase 1/2 trial update reveals Rhenium-186 Obisbemeda's favorable safety profile and potential efficacy in recurrent glioblastoma treatment.
The trial achieved a mean Phase 2 absorbed dose of 300 Gy, with 89% of patients exceeding the 100 Gy minimal dose threshold, indicating effective drug delivery.

Henlius to Present Latest Clinical Data of HLX22 at 2024 ESMO Gastrointestinal Cancers Congress

Henlius is set to share the latest clinical data from its phase 2 study of HLX22, a novel anti-HER2 monoclonal antibody, at the 2024 ESMO Gastrointestinal Cancers Congress. The study, led by Professor Jin Li, explores the combination of HLX22 with HANQUYOU and chemotherapy for treating HER2-positive gastric/gastroesophageal junction cancer, showing promising results in prolonging progression-free survival and enhancing antitumour response.

Greenwich LifeSciences' Flamingo-01 Trial Expands into Europe and Broadens Patient Enrollment

Greenwich LifeSciences' Flamingo-01 Phase III trial, evaluating GLSI-100 for breast cancer recurrence prevention, has been approved for expansion into Europe, including Spain, France, Germany, Italy, and Poland.
The Flamingo-01 trial will activate 105 sites in Europe, with site initiation visits starting as early as March 4, 2024, aiming to enroll more patients and accelerate the study.

Henlius Highlights Positive Clinical Data for HLX22 and Serplulimab in Gastrointestinal Cancers

Henlius' HLX22, combined with trastuzumab and chemotherapy, shows improved survival and antitumor response in HER2-positive gastric/gastroesophageal junction (G/GEJ) cancer patients.
Serplulimab, plus bevacizumab biosimilar HLX04 and XELOX, significantly prolonged progression-free survival (PFS) in metastatic colorectal cancer (mCRC) patients.

Reference News

[1]
Greenwich Lifesciences Provides Update On Commercial Manufacturing
menafn.com · Jan 22, 2025

Greenwich LifeSciences progresses with FLAMINGO-01 Phase III trial for GLSI-100, aiming to prevent breast cancer recurre...

[2]
Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01
stocktitan.net · Mar 17, 2025
[3]
Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01
manilatimes.net · Mar 17, 2025
[4]
Greenwich LifeSciences gains after GP2 commercial manufacturing update
seekingalpha.com · Jan 22, 2025

Greenwich LifeSciences (GLSI) stock rose after updating on GP2's commercial manufacturing, currently in FLAMINGO-01 tria...

[5]
Greenwich LifeSciences provides update on FLAMINGO-01 trial
markets.businessinsider.com · Mar 17, 2025
[6]
Greenwich LifeSciences Provides Update on Commercial Manufacturing
finance.yahoo.com · Jan 22, 2025

In 2024, advancements were made in GP2 manufacturing and GLSI-100 reconstitution, potentially leading to new patent fili...

[7]
Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01
finance.yahoo.com · Mar 17, 2025
[8]
Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01
markets.businessinsider.com · Mar 17, 2025
[9]
Greenwich LifeSciences Provides Update on Corporate Events - GlobeNewswire
globenewswire.com · Nov 18, 2024

Greenwich LifeSciences updates on 2024 events, including conferences and sponsorships, and details its Phase III FLAMING...

[10]
Greenwich Lifesciences Provides Update On Open Label Safety Data From FLAMINGO-01
menafn.com · Mar 17, 2025
[11]
Greenwich LifeSciences Provides Update on Commercial Manufacturing
markets.businessinsider.com · Jan 22, 2025

Greenwich LifeSciences advances GP2 manufacturing for GLSI-100, aiming for US BLA submission. Progress includes 2023-202...

[12]
Greenwich LifeSciences provides update on commercial manufacturing of GP2
markets.businessinsider.com · Jan 22, 2025

Greenwich LifeSciences (GLSI) advanced GP2's commercial manufacturing, producing three lots in 2023 and vial-filled lots...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy